Combined Novel 3D Cell Culture and Biospectroscopy: Osteoporosis
Research type
Research Study
Full title
Combined Novel 3D Cell Culture and Biospectroscopy; personalising Osteoporosis therapeutics
IRAS ID
220163
Contact name
JG Kerns
Contact email
Sponsor organisation
Lancaster University
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Osteoporosis is a debilitating progressive disease associated with ageing, particularly postmenopausal women. It is a serious international healthcare burden, which will increase as the ageing population grows. It is caused by a reduction in bone mineral density, which leads to fragile bones with an increased risk of fracture upon a low impact fall. There are now many different treatments available, the first line is a bisphosphonate. However, many may try different types or need to swap after several years. This is partly due to the x-ray radiation risk associated with the diagnostic tool, which is only recommended to be used every 3 years so the impact of the treatment cannot be easily assessed for improved bone quality. Secondly, bisphosphonates have been strongly linked to atypical fractures (an unusual mid-thigh fracture), which does not heal well and often leads to morbidity. The overall costs associated with diagnosis, treatment, management and fracture repair are a huge health-economic burden and severely reduces quality of life for the individual.
The aim of this project is to provide a stratified medicine approach to osteoporosis treatment, which establishes the optimal treatment for the individual, off-line in a laboratory. This will leads to a reduction in a the amount of time taken to determine appropriate treatment, improved quality of life, and a reduction in atypical fractures associated with long-term treatment.REC name
London - Surrey Borders Research Ethics Committee
REC reference
17/LO/0605
Date of REC Opinion
27 Apr 2017
REC opinion
Further Information Favourable Opinion